Trial reportPediatric obesity2019
Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity.
Trial report in Pediatric obesity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.European journal of nutrition · 2021Pooled it
- Utility of theClinical and translational science · 2022Trial
- Exploring the Influence of Obesity and CYP2 C19 Genotype on Lansoprazole Pharmacokinetics in Pediatric Patients: A Population Modeling Approach.Clinical pharmacokinetics · 2025Article
- Impact of obesity and roux-en-Y gastric bypass on the pharmacokinetics of (R)- and (S)-omeprazole and intragastric pH.CPT: pharmacometrics & systems pharmacology · 2024Article
- Evaluation of Obesity-Related Physiological Changes on Pantoprazole Clearance in Children Using a Population Pharmacokinetic Approach.Journal of clinical pharmacology · 2024Article
- Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children.Clinical and translational science · 2024Article
- Management of the pediatric patient with asthma and obesity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024Review
- Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research.Expert opinion on drug metabolism & toxicology · 2023Review
- Drug dosing in children with obesity: a narrative updated review.Italian journal of pediatrics · 2022Review
- Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis.Critical care (London, England) · 2021Review
- Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children.Paediatric drugs · 2019Review
- Considerations for Implementing Precision Therapeutics for Children.Clinical and translational science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundChildren with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing.
objectiveTo prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity.
methodsMethods: Sixty-two children (6-17 years) received a one-time oral dose of liquid pantoprazole (1.2 mg kg
resultsAdjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent drug clearance (CL/F) was reduced 50% in children with vs. without obesity (p=0.03). LBW-based dosing compensated for this reduction in CL/F (p = 0.15).
conclusionTo achieve comparable systemic PPI exposures for children with and without obesity, we recommend using LBW, rather than TBW-based dosing for pantoprazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.